GENE ONLINE|News &
Opinion
Blog

Bristol Myers Squibb
R&D TIGIT
BMS Wins Agenus’ anti-TIGIT Asset to Bolster I-O Pipeline
2021-05-21
Trials & Approvals Gastric Cancer
BMS’s Drug Bags First FDA-Approved Immunotherapy Tag for Initial Treatment of Gastric Cancer
2021-04-19
Trials & Approvals
BMS, bluebird’s Multiple Myeloma Drug Becomes First BCMA Targeting CAR-T Therapy to Snag FDA Okay
2021-03-28
M&A Gastric Cancer
Amgen Signs $1.9 Billion Worth Cancer Deal, Nurtures Growth Aspirations in Asia with New Oncology Assets
2021-03-07
R&D Molecular Templates
Texas Biopharma Inks $1.3 Billion Worth BMS Deal to Develop Engineered Toxin Bodies
2021-02-14
Trials & Approvals Tyrosine Kinase 2
Bristol Myers Squibb Registers Another Trial Win for its Psoriasis Med
2021-02-03
Special COVID-19
GeneOnline’s Top Mergers and Acquisitions of 2020
2020-12-30
Trials & Approvals NSCLC
Jounce Discontinues Phase 2 NSCLC Trial After its Combo Therapy with Ipilimubab Folds
2020-11-06
Trials & Approvals
Bristol Myers Squibb’s Deucravacitinib Impresses in Phase 3 Psoriasis Trial
2020-11-04
Trials & Approvals
FDA Accepts Opdivo, Cabometyx Combo’s Priority Review Applications
2020-10-21
Trials & Approvals S1P
Bristol Myers Squibb’s Zeposia Shines in Ulcerative Colitis Trial
2020-10-13
Funding Heart Disease
Why is Bristol Myers Squibb Investing $13.1 Billion in MyoKardia?
2020-10-06
Trials & Approvals
FDA Approves Treatment for Aggressive Form of Mesothelioma After Sixteen Long Years
2020-10-04
Trials & Approvals PD-L1
BMS Enters Esophageal Cancer Therapy Area Amidst High Competition
2020-09-27
Trials & Approvals Epigenetic Modifier
Bristol Myers Squibb Notches Key Regulatory Win for Oral Formulation of Epigenetic Modifier
2020-09-06
1 2 3 4
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top